FDA Has Key New Constituency for REMS: Advisory Committee Members
This article was originally published in RPM Report
Executive Summary
FDA’s advisory committee members seem to be adopting the new post-marketing REMS authority with more enthusiasm than FDA’s own staff. Many of the advisory committee members – especially people who have served on the Drug Safety & Risk Management Advisory Committee – are jumping at the middle ground solution (between approval and rejection) offered by REMS. The Avandia re-review on July 13-14 demonstrated the strong appeal of REMS in a tough regulatory situation.
You may also be interested in...
Endo’s Aveed and the State of REMS After Five Years
The REMS era is five years old – almost as old as the original NDA filing for Endo’s long-acting testosterone injection Aveed. A recent FDA advisory committee review of that application (now on its third cycle) captures many of the current themes in REMS policy.
FDA Re-arms DSaRM: Recruits Eight Veterans from Safety/Surveillance World
The new group of Drug Safety & Risk Management Advisory Committee members comprises a lot of familiar faces. FDA has made use of its extensive outside academic connections, research grants and post-graduate training programs to bring in eight members for the Classes of 2013 and 2014. Most of them have been getting extensive on-the-job training with the advisory committee already.
FDA Re-arms DSaRM: Recruits Eight Veterans from Safety/Surveillance World
The new group of Drug Safety & Risk Management Advisory Committee members comprises a lot of familiar faces. FDA has made use of its extensive outside academic connections, research grants and post-graduate training programs to bring in eight members for the Classes of 2013 and 2014. Most of them have been getting extensive on-the-job training with the advisory committee already.